Compare Figs Inc (FIGS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Recursion Pharmaceuticals Inc — how do they compare? Figs Inc trades at $9.98 (market cap $1.66B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.75B). The key difference: Figs Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and Figs Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FIGS | RXRX | |
|---|---|---|
Market Cap | $1.66B | $1.75B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $6.79 |
52-Week Low | $5.81 | $2.84 |
Enterprise Value | $1.44B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $10.08, up 3.7% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $631.1M in 2025 (Zacks Investment Research, 2026-05-07), but net cash flow remains negative. Analyst consensus is Buy with a $19.50 target, though technical indicators show selling pressure.
Outlook hinges on global expansion and margin management amid cost pressures. Risks include competitive threats and volatile cash flows, but strong customer growth and premium positioning offer upside if execution improves.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
